Impulse Dynamics
17
6
8
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
17.6%
3 terminated/withdrawn out of 17 trials
62.5%
-24.0% vs industry average
0%
0 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Assessment of CCM in HF With Higher Ejection Fraction
Role: lead
CCM OPEN HF Registry
Role: lead
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
Role: lead
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Role: lead
Assessment of Combined CCM and ICD Device in HFrEF
Role: lead
The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
Role: collaborator
CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)
Role: lead
Cardiac Contractility Modulation in Chagas Heart Disease
Role: collaborator
Arrythmia Burden in Cardiac Contractility Modulation (CCM)
Role: collaborator
CCM in Heart Failure With Preserved Ejection Fraction
Role: lead
Optimizer System With ODOCOR II CCM™ Leads
Role: lead
Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System
Role: lead
Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C
Role: lead
Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure
Role: lead
Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
Role: lead
Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System
Role: lead
Effects of CCM-therapy in Patients With Heart Failure
Role: collaborator
All 17 trials loaded